These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23472071)

  • 1. Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
    Matthews LT; Sibeko S; Mansoor LE; Yende-Zuma N; Bangsberg DR; Karim QA
    PLoS One; 2013; 8(3):e56400. PubMed ID: 23472071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
    Naranbhai V; Abdool Karim SS; Altfeld M; Samsunder N; Durgiah R; Sibeko S; Abdool Karim Q; Carr WH;
    J Infect Dis; 2012 Oct; 206(7):993-1001. PubMed ID: 22829639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
    MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
    AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
    Wei X; Hunt G; Abdool Karim SS; Naranbhai V; Sibeko S; Abdool Karim Q; Li JF; Kashuba AD; Werner L; Passmore JA; Morris L; Heneine W; Johnson JA
    J Infect Dis; 2014 Jun; 209(12):1916-20. PubMed ID: 24436453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Delany-Moretlwe S; Lombard C; Baron D; Bekker LG; Nkala B; Ahmed K; Sebe M; Brumskine W; Nchabeleng M; Palanee-Philips T; Ntshangase J; Sibiya S; Smith E; Panchia R; Myer L; Schwartz JL; Marzinke M; Morris L; Brown ER; Doncel GF; Gray G; Rees H
    Lancet Infect Dis; 2018 Nov; 18(11):1241-1250. PubMed ID: 30507409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
    Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
    Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
    Trials; 2014 Dec; 15():496. PubMed ID: 25527071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
    Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
    J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
    Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
    Trials; 2011 Mar; 12():67. PubMed ID: 21385354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Choopanya K; Martin M; Suntharasamai P; Sangkum U; Mock PA; Leethochawalit M; Chiamwongpaet S; Kitisin P; Natrujirote P; Kittimunkong S; Chuachoowong R; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Hendrix CW; Vanichseni S;
    Lancet; 2013 Jun; 381(9883):2083-90. PubMed ID: 23769234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
    Williams BG; Abdool Karim SS; Karim QA; Gouws E
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
    Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
    AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
    Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
    AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
    AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.